Clinical Trial

SSGJ-707 in Advanced Non-Small Cell Lung Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 24, 2025 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of SSGJ-707 comparing Pembrolizumab in subjects with advanced NSCLC whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-12.
Status change: Not Yet Recruiting → Recruiting 2025-06-23
Trial Details
NCT Number NCT06980272
Lead Sponsor Shenyang Sunshine Pharmaceutical Co., LTD.
Conditions Advanced Non-Small Cell Lung Cancer
Enrollment 420 participants
Start Date 2025-06-20
Primary Completion 2026-07-30 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-24